TB-500
Also known as: Thymosin Beta-4 Fragment
Clinical Status
Preclinical — No human clinical trials. FDA Category 2. WADA prohibited.
Mechanism of Action
Derived from the active region of Thymosin Beta-4. Promotes cell migration by binding to and sequestering actin. Upregulates actin expression, promotes angiogenesis, reduces inflammation, and facilitates wound healing.
Dosing Defaults
Dose
2-2.5 mg
Frequency
2x weekly
Administration
Subcutaneous or intramuscular injection
Timing
Morning or evening
Food
with or without
Duration
4-6 weeks loading, then maintenance
Dose range: 2-10 mg per week during loading phase
Long half-life makes timing flexible. Consistency matters more than specific time.
Side Effects
- •Injection site reactions
- •Headache
- •Fatigue
- •Nausea
- •May trigger histamine release
Contraindications & Warnings
- ⚠Active cancer or cancer history
- •Not medical advice
- •FDA Category 2
- •WADA prohibited
Compare
Compare TB-500 with another peptide side-by-side.
Ad
Related Healing & Recovery Peptides
This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.